Design Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2020 |
|---|---|---|---|
| Revenue | $0 | $0 | $226.0K |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $59.1M | $44.4M | $6.1M |
| SG&A Expense | $20.3M | $18.0M | $2.5M |
| Operating Income | $-79.5M | $-62.4M | $-8.3M |
| Operating Margin | — | — | -3,685.8% |
| Interest Expense | — | — | — |
| Pretax Income | — | — | — |
| Income Tax Expense | $0 | $0 | — |
| Net Income | $-69.8M | $-49.6M | $-8.3M |
| Net Margin | — | — | -3,663.7% |
| EPS (Basic) | $-1.22 | $-0.88 | $-0.52 |
| EPS (Diluted) | $-1.22 | $-0.88 | $-0.52 |
| Shares Outstanding (Basic) | 57.3M | 56.6M | 16.0M |
| Shares Outstanding (Diluted) | 57.3M | 56.6M | 16.0M |
| Dividends Per Share | — | — | — |